Cleaved-F12 (R372) Antibody
Description
Technical Properties
The antibody possesses several key technical characteristics that define its utility in laboratory settings:
This antibody is produced through immunization of rabbits with a synthesized peptide derived from the internal region of human Factor XII HC, specifically targeting the amino acid sequence between positions 323-372 . The resulting antiserum undergoes rigorous purification through affinity chromatography to isolate specific immunoglobulins with high binding affinity for the target epitope .
Physical and Chemical Properties
The Cleaved-F12 (R372) Antibody is formulated for optimal stability and performance in research applications:
The formulation provides extended shelf life while maintaining antibody activity and specificity. The inclusion of glycerol helps prevent freeze damage during storage, while BSA reduces non-specific binding and sodium azide serves as a preservative to inhibit microbial growth .
Target Biological Context and Significance
Factor XII (F12), also known as Hageman Factor, plays a crucial role in the blood coagulation process and related physiological pathways. Understanding the cleaved form at arginine 372 provides insights into activation mechanisms within these systems.
Factor XII Structure and Function
Coagulation Factor XII circulates in blood as a zymogen (inactive precursor) and undergoes specific proteolytic cleavage during activation:
Factor XII participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. It activates coagulation factors VII and XI as part of the intrinsic coagulation pathway. Interestingly, defects in the F12 gene do not cause clinical symptoms, with the sole effect being prolonged whole-blood clotting time .
Significance of R372 Cleavage
The arginine 372 position represents a critical cleavage site in the activation process of Factor XII:
The cleavage at R372 results in the formation of activated Factor XII fragments, creating alpha-Factor XIIa. This activated form plays essential roles in initiating the contact activation pathway of the coagulation cascade and participating in inflammatory responses . The Cleaved-F12 (R372) Antibody specifically recognizes this cleaved form, enabling researchers to distinguish between inactive and active states of the protein in experimental contexts .
Research Applications and Methodologies
The Cleaved-F12 (R372) Antibody serves as a valuable tool in multiple research applications, particularly in the investigation of coagulation pathways and related physiological processes.
Validated Applications
The antibody has been validated for specific research techniques:
Western blot analysis has demonstrated the antibody's ability to detect cleaved Factor XII in various cell types, including 293 cells treated with etoposide . This application provides researchers with a means to investigate Factor XII activation under different experimental conditions, including response to stressors or potential therapeutic agents.
Experimental Considerations
When working with the Cleaved-F12 (R372) Antibody, several considerations can optimize experimental outcomes:
For optimal results in western blot applications, researchers should consider standard protein loading of 20-30 μg per lane and standard transfer protocols to nitrocellulose or PVDF membranes. For detection, both chemiluminescent and fluorescent secondary antibody systems are compatible with this primary antibody .
Quality Control and Manufacturing Standards
Commercial Cleaved-F12 (R372) Antibody products undergo rigorous quality control processes to ensure consistency, specificity, and performance in research applications.
Validation Methods
Manufacturers employ several validation techniques to confirm antibody quality:
| Validation Method | Purpose |
|---|---|
| Western Blot Analysis | Confirms specific binding to target protein at expected molecular weight |
| Peptide Competition | Verifies epitope specificity through signal abolishment with immunizing peptide |
| Cross-Reactivity Testing | Ensures minimal non-specific binding to related proteins |
| Batch Consistency | Maintains consistent performance across manufacturing lots |
These validation steps are critical in ensuring that researchers receive consistent and reliable antibody products for their experimental needs . Manufacturers typically provide validation images showing the antibody's performance in western blot applications, often demonstrating detection of cleaved Factor XII in specific cell types like 293 cells .
Research Applications and Experimental Design
Cleaved-F12 (R372) Antibody enables various research investigations into coagulation pathways, inflammatory responses, and related physiological processes.
Current Research Applications
The antibody finds utility in several research areas:
| Research Area | Application |
|---|---|
| Coagulation Pathway Studies | Investigating Factor XII activation in response to various stimuli |
| Inflammatory Response Research | Examining the role of activated Factor XII in inflammation |
| Pharmacological Studies | Assessing the effects of potential therapeutic agents on Factor XII activation |
| Disease Models | Studying Factor XII activation in various pathological conditions |
By specifically detecting the cleaved form of Factor XII at R372, researchers can gain insights into activation mechanisms within these systems and potentially identify novel therapeutic targets .
Experimental Design Considerations
When incorporating Cleaved-F12 (R372) Antibody into experimental workflows, researchers should consider:
Appropriate controls are essential for reliable interpretation of results, including positive controls (samples known to contain cleaved Factor XII) and negative controls (samples without the target or with blocking peptide). Cell treatment conditions may need to be optimized to induce Factor XII cleavage, as demonstrated in validation studies using etoposide treatment of 293 cells .
For western blot applications, optimization of primary antibody concentration within the recommended range (1:500-1:2000) may be necessary depending on specific sample types and detection methods. Similar optimization for ELISA applications should consider the higher dilution recommendation (1:20000) .
Limitations and Future Directions
While Cleaved-F12 (R372) Antibody provides valuable research capabilities, understanding its limitations and potential future applications is important for advancing scientific knowledge.
Current Limitations
Several constraints should be considered when working with this antibody:
All commercial sources emphasize that Cleaved-F12 (R372) Antibody is strictly for research use only (RUO) and must not be used in diagnostic or therapeutic applications . This restriction reflects regulatory requirements and the antibody's validation status.
As a polyclonal antibody, lot-to-lot variation may occur, potentially affecting consistency in long-term studies. Additionally, the antibody's validation has focused primarily on western blot and ELISA applications, with limited data on other potential techniques such as immunohistochemistry or immunofluorescence .
Future Research Directions
Potential future developments with Cleaved-F12 (R372) Antibody include:
Extension of validation to additional applications could expand the antibody's utility in research contexts. Development of monoclonal variants could provide greater consistency and potentially higher specificity. Integration with emerging technologies, such as multiplex protein analysis platforms or advanced imaging techniques, could enhance our understanding of Factor XII activation dynamics in complex biological systems .
Investigation of Factor XII activation in various disease models using this antibody could provide insights into pathological mechanisms and potential therapeutic interventions targeting the coagulation and inflammatory pathways .
Product Specs
Target Background
- Heterozygous F12 mutation decreases plasma FXII activity by approximately half, causing moderate FXII deficiency in a Chinese population. PMID: 29587641
- Elevated FXII activity levels are observed in the plasma of multiple sclerosis patients during relapse. PMID: 27188843
- Defective FXII contact activation provides thromboprotection, while excessive activation underlies the swelling disorder hereditary angioedema type III. This review comprehensively explores the molecular basis of FXII contact activation and its associated disease states. PMID: 28346966
- Accumulation of FXII in acute respiratory distress syndrome lungs may contribute to the release of pro-inflammatory mediators, thereby regulating lung inflammation. PMID: 28816340
- Data suggest that the homozygous p.Gly341Arg mutation in coagulation factor XII (FXII), caused by consanguineous marriage, likely underlies the congenital FXII deficiency in the pedigree. PMID: 29419864
- FXII deficiency impairs thrombosis in animal models without inducing abnormal bleeding. Recent research has established the FXIIa-driven contact system as a promising target for anticoagulant and anti-inflammatory drugs. This review focuses on the biochemistry of the contact system, its regulation by endogenous and exogenous inhibitors, and its roles in disease states. PMID: 28743596
- Results demonstrate that the solution composition and surface properties of the material both contribute to the observation of contact activation. Notably, FXII activation is not specific to anionic surfaces as previously believed. PMID: 28514863
- An independent association between FXII levels and the risk of hemorrhagic stroke was observed in a Swedish population. PMID: 28433996
- This study analyzes how FXII reacts to surface materials, which can be applied to understanding the activities of FXII in its natural environment [review]. PMID: 27282310
- Beta-amyloid interacts with fibrinogen and factor XII. These interactions can lead to increased clotting, abnormal clot formation, persistent fibrin deposition, and the generation of proinflammatory molecules. PMID: 28661939
- Abeta activates FXII, resulting in FXI activation and thrombin generation in human plasma, thus establishing Abeta as a potential driver of prothrombotic states. PMID: 26613657
- Results support a model for the induction of contact activation where activity intrinsic to single-chain FXII initiates alphaFXIIa and alpha-kallikrein formation on a surface. AlphaFXIIa, with support from alpha-kallikrein, subsequently accelerates contact activation and is responsible for the full procoagulant activity of FXII. PMID: 28069606
- The XPNPEP2 c-2399A and ACE insertion/deletion polymorphisms analyzed in a population of patients with hereditary angioedema with F12 mutation were not a major determinant of disease expression. PMID: 27788882
- In the presence of platelet polyphosphate and the downstream substrate fibrin, alphaFXIIa is a highly efficient and favorable plasminogen activator. PMID: 27694320
- Six distinct mutations, including three missense mutations (Gly341Arg, Glu502Lys and Gly542 Ser), one insertion (7142insertC) and two deletions (5741-5742 delCA and 6753-6755delACA), were identified on the F12 gene. Three of these mutations (Gly341Arg, 5741-5742delCA and 6753-6755delACA) are reported here for the first time. PMID: 27003566
- The present findings suggest that homozygous FXII-HAE mutation status leads to a severe phenotype in both females and males, and to an increased risk of manifest symptoms in males. PMID: 26392288
- As the factor XII pathway specifically contributes to thrombosis but not hemostasis, interference with this pathway provides a unique opportunity for safe anticoagulation without associated excess bleeding. This review summarizes current knowledge on factor XII functions, activators, and inhibitors. PMID: 25609114
- It is concluded that F12-46C/T carriage acts as an independent modifier of hereditary angioedema due to C1-INH deficiency severity. PMID: 26248961
- Active neutrophil extracellular traps formation can induce factor XII-mediated coagulation activation in patients with disseminated intravascular coagulation with poor prognosis. PMID: 26706311
- Findings report the first instance of FXII mutations causing angioedema in a Brazilian family with normal CI inhibitor status. PMID: 25816745
- Results support the significance of the contact activation pathway-dependent TG as a risk factor for ischemic stroke, and indicate the importance of F12 SNPs for TG ex vivo and in vivo. PMID: 26286125
- Genotyping these subjects revealed that carriers of the minor alleles at the two loci - F12 and KLKB1 - had a significant association with reduced levels of active plasma renin. PMID: 26969407
- The results provide a crucial foundation for the diagnosis of FXII deficiencies in Chinese. PMID: 26105808
- We hypothesize that FXIIa first strengthens the clot structure during clot formation and subsequently contributes towards fibrinolysis. PMID: 26153047
- Women with low FXII levels might have an increased risk of premature delivery at < 34 GW. PMID: 25879167
- This study provides the structural basis for understanding FXII substrate recognition and zymogen activation. PMID: 25604127
- Data illustrate a critical role for polyphosphate/factor XII-triggered coagulation in prostate cancer-associated thrombosis with implications for anticoagulation without therapy-associated bleeding in malignancies. PMID: 26153520
- The results of this study characterize the mechanism of HAEIII and establish FXII inhibition as a potential therapeutic strategy to interfere with excessive vascular leakage in HAEIII. PMID: 26193639
- This study explores the influence of FXII 46C/T on further pregnancy outcomes. PMID: 25489738
- This study suggests that C1-inh polymers activate the FXII-dependent kallikrein-kinin system in hereditary angioedema. PMID: 25800206
- The heterozygous mutation of g.8597G>A identified in exon 13 of the FXII gene is associated with hereditary coagulation factor XII deficiency. PMID: 26037346
- An F12 mutation is the primary predictor of FXII-HAE, with disease expression influenced by individual variations in kinin degradation enzyme activities. PMID: 25134986
- Authors report, for the first time in Brazil, a mutation in the F12 gene as a likely cause of HAE with normal C1-INH in patients with recurrent attacks of angioedema and/or abdominal pain. PMID: 25790805
- In a cohort with hereditary angioedema, four families carried the p.Thr309Lys mutation in the F12 gene. PMID: 25744496
- Abeta42-mediated contact system activation is driven by factor XII and can occur in the AD circulation. PMID: 25775543
- Heparan sulfate enhances FXIIa binding capacity and consequently migration of human lung fibroblasts isolated from fibrotic lungs. PMID: 25589788
- We identified the 72-bp F12 deletion in two Turkish women with hereditary angiodema-FXII. The mutation was located at the exon 9/intron 9 border and involved the proline-rich region of the factor XII protein (FXII). PMID: 25113305
- FXIIa was increased three-fold in ESRD patients relative to control plasma. After conversion to nocturnal hemodialysis, both DeltaMAP and DeltaTPR correlated with DeltaFXIIa. PMID: 24733030
- In hypercortisolemic patients, no significant disorders are present concerning FXII concentrations due to the C46T polymorphism of its gene promoter. PMID: 24691729
- FVIIa- and FXIIa-triggered coagulation pathways have distinct but complementary roles in atherothrombus formation. PMID: 24855058
- [review] As it forms, activated factor XII converts prekallikrein (PK) to kallikrein; kallikrein cleaves high-molecular-weight kininogen to release bradykinin. PMID: 24388213
- Data suggest factor XII binding/autoactivation are increased on the surface of hantavirus-infected vascular endothelium; thus, activation of the kallikrein-kinin system during hantavirus infection could have profound implications on capillary permeability. PMID: 23874198
- This study generated a specific and potent FXII/FXIIa aptamer anticoagulant that offers targeted inhibition of discrete macromolecular interactions involved in the activation of the intrinsic pathway of blood coagulation. PMID: 23692437
- Using different coagulation assays, it was shown that platelet contribution to whole blood coagulation was unrelated to the generation of activated FXII in vitro. PMID: 23896408
- Mutation in the F12 gene is a prerequisite for the expression of hereditary angioedema disease symptoms, but other factors may have protective or aggravating effects on clinical features. PMID: 23849223
- These results may confirm the importance of the proline-rich region of factor XII protein in edema formation. PMID: 23994767
- Immobilized Ni(2+) and Cu(2+) bind FXII, FXI, and high molecular weight kininogen with high affinity and stimulate activation of the contact pathway, driving FXII-mediated coagulation. PMID: 22905925
- The F12 46TT genotype is strongly associated with cerebral venous thrombosis in the south Indian population. PMID: 22500857
- The goal of this review is to summarize the in vivo functions of FXII, with a special focus on its functions in thrombosis and vascular biology. PMID: 22993391
Q&A
What is Cleaved-F12 (R372) Antibody and what epitope does it recognize?
Cleaved-F12 (R372) Antibody is a rabbit polyclonal antibody specifically designed to detect endogenous levels of activated Factor XII HC protein fragments. This antibody targets the amino acid sequence in the 323-372 region of human Factor XII HC, with particular specificity for the cleavage site adjacent to arginine 372 (R372) .
The antibody recognizes the neo-epitope formed when Factor XII undergoes proteolytic activation, converting from a single-chain zymogen to its cleaved, activated form. This specific recognition makes it an invaluable tool for studying Factor XII activation in coagulation cascades and related pathways.
Factor XII (F12), also known as Hageman Factor, circulates in blood as an inactive zymogen. During activation, it undergoes proteolytic cleavage that converts it to a two-chain serine protease with a heavy chain (alpha-factor XIIa) and a light chain, with the antibody specifically recognizing this cleavage event .
What are the technical specifications of this antibody?
Cleaved-F12 (R372) Antibody has the following key technical characteristics:
| Property | Specification |
|---|---|
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Primary Reactivity | Human |
| Secondary Reactivity | Rat, Mouse (varies by product) |
| Conjugation | Unconjugated |
| Form | Liquid |
| Concentration | 1 mg/mL |
| Formulation | PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide |
| Recommended Dilution (WB) | 1:500-1:2000 |
| Recommended Dilution (ELISA) | 1:20000 |
| Storage Conditions | -20°C for up to 1 year from date of receipt |
| Purification Method | Affinity chromatography using epitope-specific immunogen |
| Observed Molecular Weight | ~41 kDa |
| Calculated Molecular Weight | ~68 kDa |
The antibody is produced through immunization of rabbits with a synthesized peptide derived from the internal region of human Factor XII HC and undergoes rigorous purification through affinity chromatography to isolate specific immunoglobulins with high binding affinity for the target epitope .
What is the biological significance of Factor XII cleavage at R372?
Factor XII (F12) plays a crucial role in initiating blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. The cleavage at R372 represents a key step in Factor XII activation, which has significant physiological implications.
During activation, prekallikrein is cleaved by Factor XII to form kallikrein, which then cleaves Factor XII first to alpha-factor XIIa. Subsequently, trypsin cleaves it to beta-factor XIIa. Alpha-factor XIIa activates Factor XI to Factor XIa, thus propagating the intrinsic coagulation cascade .
Understanding this specific cleavage event provides insights into coagulation disorders, thrombotic conditions, and inflammatory responses. The ability to detect and quantify cleaved Factor XII at R372 can help researchers investigate these pathways in both normal physiology and disease states .
What are the validated applications for Cleaved-F12 (R372) Antibody?
The primary validated applications for Cleaved-F12 (R372) Antibody include:
-
Western Blotting (WB): The antibody has been validated for Western Blot analysis with recommended dilutions of 1:500-1:2000. This application allows researchers to detect the cleaved form of Factor XII in protein lysates from various tissues and cell lines .
-
Enzyme-Linked Immunosorbent Assay (ELISA): The antibody has shown high sensitivity in ELISA applications with a recommended dilution of 1:20000. This makes it suitable for quantitative detection of cleaved Factor XII in serum or plasma samples .
While these are the primary validated applications, researchers have also explored its use in immunohistochemistry and immunoprecipitation studies, although additional validation may be required for these applications. When designing experiments, it's important to incorporate appropriate positive and negative controls to ensure specificity and reliability of results .
How can researchers optimize Western Blot protocols for Cleaved-F12 (R372) Antibody?
Optimizing Western Blot protocols for Cleaved-F12 (R372) Antibody requires careful attention to several factors:
What experimental controls should be included when using this antibody?
When designing experiments with Cleaved-F12 (R372) Antibody, several critical controls should be included:
-
Positive Control: Samples known to contain activated Factor XII, such as serum activated with kaolin or ellagic acid, can serve as positive controls for validating antibody performance.
-
Negative Control: Samples from Factor XII-deficient individuals or Factor XII knockout animal models can serve as specificity controls. Additionally, pre-absorption of the antibody with the immunizing peptide can be used to confirm specificity .
-
Loading Control: When performing Western Blot analysis, appropriate loading controls (such as β-actin, GAPDH, or total protein staining) should be included to normalize protein loading across samples .
-
Cleavage Controls: Including samples with known Factor XII activators (like prekallikrein, kallikrein, or specific proteases) can help validate the antibody's ability to specifically detect the cleaved form at R372 .
-
Secondary Antibody Control: A no-primary antibody control should be included to assess potential non-specific binding of the secondary antibody .
How can researchers differentiate between different cleavage products of Factor XII?
Factor XII undergoes multiple cleavage events during its activation, and differentiating between these products requires careful experimental design:
-
Epitope Specificity: Cleaved-F12 (R372) Antibody specifically recognizes the neo-epitope created after cleavage at R372. To distinguish between different cleavage products, researchers can use a panel of antibodies targeting different regions or cleavage sites of Factor XII .
-
Molecular Weight Analysis: Different cleavage products of Factor XII have distinct molecular weights. Alpha-Factor XIIa and beta-Factor XIIa can be differentiated based on their migration patterns in gel electrophoresis. The cleaved form recognized by this antibody typically appears at approximately 41 kDa, differing from the calculated molecular weight of 68 kDa for the full-length protein .
-
Sequential Immunoprecipitation: For complex samples, sequential immunoprecipitation using antibodies against different domains of Factor XII can help isolate and characterize specific cleavage products .
-
Mass Spectrometry Analysis: For definitive identification of cleavage products, researchers can combine immunoprecipitation with mass spectrometry analysis to precisely map the cleavage sites and confirm the identity of the detected fragments.
What experimental approaches can be used to study Factor XII activation kinetics?
Studying the kinetics of Factor XII activation requires sophisticated experimental approaches:
-
Time-Course Experiments: Researchers can design time-course experiments where Factor XII is exposed to activators (such as kallikrein or artificial surfaces) and samples are collected at various time points. The Cleaved-F12 (R372) Antibody can then be used to detect the appearance and accumulation of the cleaved form over time.
-
Quantitative Western Blotting: By combining Western blotting with densitometry analysis, researchers can quantify the relative amounts of cleaved Factor XII at different time points or under different experimental conditions .
-
ELISA-Based Kinetic Assays: The high sensitivity of this antibody in ELISA applications (1:20000 dilution) makes it suitable for developing quantitative assays to measure Factor XII activation kinetics in real-time or in endpoint analyses .
-
Surface Plasmon Resonance: For detailed kinetic studies, the Cleaved-F12 (R372) Antibody can be immobilized on SPR chips to capture cleaved Factor XII from reaction mixtures, allowing real-time monitoring of activation processes.
-
Fluorescent Reporter Systems: Combining the antibody with fluorescent detection systems can enable real-time monitoring of Factor XII activation in cell-based or in vitro assays .
How can the antibody be used to investigate Factor XII's role in pathological conditions?
The Cleaved-F12 (R372) Antibody offers valuable opportunities for studying Factor XII's involvement in various pathological conditions:
-
Thrombotic Disorders: Researchers can use the antibody to assess levels of activated Factor XII in patient samples with thrombotic disorders, potentially identifying correlations between Factor XII activation and disease severity or progression.
-
Inflammatory Conditions: Given Factor XII's role in bradykinin generation, the antibody can be used to investigate the relationship between Factor XII activation and inflammatory responses in conditions like hereditary angioedema or systemic inflammation .
-
Animal Disease Models: In experimental animal models of cardiovascular disease, thrombosis, or inflammation, the antibody can help track Factor XII activation status across different tissues and time points .
-
Ex Vivo Blood Systems: Using the antibody in ex vivo blood perfusion systems or microfluidic devices can help visualize and quantify Factor XII activation in response to pathological stimuli such as atherosclerotic plaques or bacterial components.
-
Translational Research: The cross-reactivity with human, rat, and mouse samples makes this antibody particularly valuable for translational research, allowing findings from animal models to be compared with human clinical samples .
What are common challenges when using Cleaved-F12 (R372) Antibody and how can they be addressed?
Researchers may encounter several challenges when working with Cleaved-F12 (R372) Antibody:
-
High Background in Western Blots: This can be addressed by optimizing blocking conditions (using 5% BSA instead of milk), increasing washing steps, and titrating the antibody concentration. The recommended dilution range of 1:500-1:2000 provides room for optimization based on specific experimental conditions .
-
Discrepancy in Molecular Weight: The observed molecular weight (~41 kDa) differs from the calculated molecular weight (~68 kDa). This is normal for the cleaved product and should not be considered a technical issue. Researchers should use appropriate molecular weight markers and positive controls to confirm band identity .
-
Sample Degradation: Factor XII can undergo spontaneous activation or degradation during sample handling. To minimize this, samples should be collected in the presence of protease inhibitors, processed quickly, and stored appropriately at -20°C or -80°C with 50% glycerol to prevent freeze-thaw damage .
-
Cross-Reactivity Issues: While the antibody has been tested for reactivity with human, rat, and mouse samples, the level of cross-reactivity may vary. Validation in the specific experimental system is recommended before proceeding with large-scale studies .
-
Lot-to-Lot Variability: As with any polyclonal antibody, there may be some lot-to-lot variability. Researchers should validate each new lot against previous standards to ensure consistent performance.
How should researchers interpret unexpected results when using this antibody?
When faced with unexpected results using Cleaved-F12 (R372) Antibody, researchers should consider the following interpretative approaches:
-
Multiple Bands in Western Blot: Additional bands may represent other cleavage products of Factor XII, degradation products, or non-specific binding. Performing peptide competition assays can help determine which bands are specific. Additionally, comparison with a total Factor XII antibody can help identify specific cleavage products .
-
No Signal Detection: This could be due to low abundance of cleaved Factor XII in the sample, improper sample preparation, or antibody degradation. Researchers should include positive controls and consider signal enhancement techniques such as chemiluminescent substrates with higher sensitivity or longer exposure times .
-
Inconsistent ELISA Results: Variability in ELISA results could stem from matrix effects, interfering substances in plasma/serum, or improper blocking. Optimizing sample dilution, using standard curves with recombinant proteins, and incorporating appropriate controls can improve consistency .
-
Species Differences: While the antibody reacts with human, rat, and mouse Factor XII, there may be species-specific differences in epitope recognition or background. Species-specific validation and optimization are recommended .
-
Activation During Sample Processing: Unintended activation of Factor XII during sample collection or processing can confound results. Comparison with samples collected under different conditions (e.g., different anticoagulants) can help identify such artifacts.
What are the optimal storage conditions for maintaining antibody activity?
The Cleaved-F12 (R372) Antibody requires specific storage conditions to maintain its activity and specificity:
-
Temperature: The antibody should be stored at -20°C for up to one year from the date of receipt. Some manufacturers also suggest -80°C as an alternative storage temperature for longer periods .
-
Formulation: The antibody is provided in a stabilizing buffer containing PBS with 50% glycerol, 0.5% BSA/rAlbumin, and 0.02% sodium azide. This formulation helps maintain antibody stability during storage .
-
Aliquoting: To avoid repeated freeze-thaw cycles, which can degrade antibody activity, the stock solution should be aliquoted into smaller volumes upon receipt. Each aliquot should be sufficient for single-use applications .
-
Thawing Procedure: When removing from storage, the antibody should be thawed slowly at 4°C or on ice rather than at room temperature to preserve its binding characteristics .
-
Working Solution Storage: Diluted working solutions should be prepared fresh for each experiment. If storage is necessary, they can be kept at 4°C for up to one week, but with potential reduction in activity over time.
How should researchers prepare working dilutions for different applications?
Preparing proper working dilutions is critical for optimal antibody performance:
-
Western Blot Applications: The recommended dilution range is 1:500-1:2000. For initial testing, researchers should prepare a dilution series (e.g., 1:500, 1:1000, 1:2000) to determine the optimal concentration for their specific sample type and detection system .
-
ELISA Applications: A higher dilution of 1:20000 is recommended for ELISA, reflecting the higher sensitivity of this detection method. Optimization may still be required based on the specific ELISA format (direct, indirect, sandwich) and detection system used .
-
Diluent Composition: Working dilutions should be prepared in a buffer containing a carrier protein (such as 1-5% BSA in TBS-T) to prevent antibody adsorption to tube walls and to maintain stability.
-
Fresh Preparation: Ideally, working dilutions should be prepared fresh for each experiment. If storage is necessary, they should be kept at 4°C for no more than a week and should not be repeatedly frozen and thawed .
-
Pre-absorption Controls: For validation of specificity, a portion of the antibody can be pre-absorbed with the immunizing peptide. This pre-absorbed antibody serves as an important negative control in optimization experiments .
How does Cleaved-F12 (R372) Antibody compare with other Factor XII detection methods?
Cleaved-F12 (R372) Antibody offers distinct advantages and limitations compared to other methods for studying Factor XII:
-
Specificity for Activation State: Unlike antibodies that detect total Factor XII, this antibody specifically recognizes the cleaved form at R372, providing direct information about Factor XII activation status. This is particularly valuable for studying activation-dependent processes .
-
Comparative Sensitivity: In Western Blot applications, the antibody shows good sensitivity at dilutions of 1:500-1:2000. In ELISA applications, it demonstrates high sensitivity at dilutions up to 1:20000. This compares favorably with functional assays for Factor XII, which often have lower sensitivity .
-
Complementarity with Activity Assays: While functional assays measure Factor XII enzymatic activity, this antibody detects the physical presence of the cleaved form. Combining both approaches provides complementary information about both the presence and functionality of activated Factor XII.
-
Spatial Information: Unlike chromogenic or functional assays, immunodetection methods using this antibody can be adapted for immunohistochemistry or immunofluorescence, potentially providing spatial information about Factor XII activation in tissue contexts .
-
Species Flexibility: The cross-reactivity with human, rat, and mouse Factor XII allows for translational research across different model systems, which is not always possible with species-specific functional assays .
What emerging research areas could benefit from applications of this antibody?
Several cutting-edge research areas could benefit from the application of Cleaved-F12 (R372) Antibody:
-
Contact System in Thromboinflammation: Recent research has highlighted the importance of the contact system, including Factor XII, in the intersection between thrombosis and inflammation. This antibody could help elucidate the activation patterns of Factor XII in various thromboinflammatory conditions.
-
Factor XII in Neurodegenerative Diseases: Emerging evidence suggests a role for the contact system in neurodegenerative disorders like Alzheimer's disease. The antibody could be used to investigate Factor XII activation in brain tissue or cerebrospinal fluid samples from relevant disease models or patients .
-
Biomarker Development: The specific detection of cleaved Factor XII could lead to the development of biomarkers for conditions associated with contact system activation, such as thrombotic disorders, hereditary angioedema, or systemic inflammation.
-
Drug Development Targeting Factor XII: As Factor XII emerges as a potential therapeutic target for thrombotic disorders without bleeding risk, this antibody could be valuable in screening compounds that inhibit Factor XII activation or in validating target engagement in preclinical studies .
-
Microfluidic and Organ-on-Chip Applications: The antibody could be integrated into advanced microfluidic systems or organ-on-chip platforms to study Factor XII activation under flow conditions or in complex tissue environments, providing insights into its behavior in more physiologically relevant settings.
